Alternatives for the Prevention of Cancer Recurrences: Immunonutrition, Cat's Claw and Rhopalurus Junceus Venom
DOI:
https://doi.org/10.36570/jduhs.2021.3.1217Keywords:
Neoplasms, epidemiology,, incidence,, mortality, recurrence, therapy, prevention, cat’s claw, immunonutrition, scorpion venom, Rhopalurus junceusAbstract
Over the years, cancer treatment has focused on its eradication once it has been detected, however, it's common to find that a large number of neoplasms redevelop in patients, which reduces their quality and life expectancy when going through surgical treatments, chemotherapy and radiotherapy schemes once again. Several studies have been developed on some alternatives for the treatment of cancer that can be used as preventive methods for relapses, such as immunonutrition that is based on the administration of amino acids that contain sulfides, fatty acids, omega 3, vitamin and some minerals; the Uncaria tomentosa which is a plant that grows like a vine under tropical trees and whose extracts can induce oxidative stress; and the poison of Rhopalurus junceus(blue scorpion) which has been shown to induce necrosis or apoptosis in different malignant cell lines. This review summarizes points in favor of the use of Immunonutrition, Uncaria tomentosa and Rhopalurus junceus venom to limit a cancer recurrence.
Downloads
References
Kumar V, Abbas AK, Aster JC. Robbins y Cotran. Patologia estructural y funcional [Internet]. 9. Espana: Elsevier Espana; 2015. [Cited 2021 July 21]. 1408 p. Ava i l able from: https ://www.el sev ier. com /books/robbins-y-cotran-patologia-estructuralyfuncional/kumar/978-84-9022-878-4.
Herrera Gomez A, Granados Garcia M. Manual de oncologia: procedimientos médico quirurgicos.
Mexico, D.F: McGraw Hill; 2013.
Urquiza MP, Gibert AG, Fuenmayor R, Bordas Als JM. Utilidad de la ultrasonografía endoscopica (USE) en Oncologia. Rev Oncol 2002; 4:358-69. doi.org/10.1007/BF02713041.
Z a imy MA, S affa r z adeh N, Mohammadi A, Pourghadamyari H, Izadi P, Sarli A, et al. New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles. Cancer Gene Ther 2017; 24:233-43. doi.org/10.1038/cgt.2017.16
ASALE R-, RAE. recidiva | Diccionario de la lengua espanola [Internet]. «Diccionario de la lengua espanola» - Edicion del ricentenario. [Cited 2021 July 21]. Available from: https://dle.rae.es/recidiva
ASALE R-, RAE. regresion | Diccionario de la lengua espanola [Internet]. «Diccionario de la lengua espanola» - Edicion del Tricentenario. [Cited 2021 July 21]. Available from: https://dle.rae.es/regresion
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M, et al. Cancer Observatory: Cancer Today [Internet]. Lyon, France: International Agency for Research on Cancer; 2013 [updated 2020 December; cited 2021 January 21]. Available from: https://gco.iarc.fr/today
Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 2016; 375:209-19. doi.org/10.1056/NEJMoa1604700
Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thurlimann B, et al. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol 2016; 34):927-35. doi.org/10.1200/JCO.2015.62.3504
Takeshita T, Yan L, Asaoka M, Rashid O, Takabe K. Late recurrence of breast cancer is associated with procancerous immune microenvironment in the primary tumor. Scientific Reports 2019; 9:16942. doi.org/10.1038/s41598-019-53482-x.
Maurizi G, D'Andrilli A, Ciccone AM, Ibrahim M, Andreetti C, Tierno S, et al. Margin Distance Does Not Influence Recurrence and Survival After Wedge Resection for Lung Cancer. Ann Thorac Surg 2015; 100:918-24. doi.org/10.1016/j.athoracsur.2015.04.064
Ochiai S, Nomoto Y, Watanabe Y, Yamashita Y, Toyomasu Y, Kawamura T, et al. The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non-small cell lung cancer: a literature review and pooled analysis. J Radiat Res (Tokyo) 2016; 57:449- 59. doi.org/10.1093/jrr/rrw075
Pugh SA, Shinkins B, Fuller A, Mellor J, Mant D, Primrose JN. Site and Stage of Colorectal Cancer Influence the Likelihood and Distribution of Disease Recurrence and Postrecurrence Survival: Data From the FACS Randomized Controlled Trial. Ann Surg 2016; 263:1143-7. doi.org/10.1097/SLA.0000000000001351
Manuel Ramirez-Rodriguez J, Aguilella-Diago V. Recidiva local en el cancer de colon y recto. Cir Esp 1 2005; 78:344-50. doi.org/10.1016/S0009-739X(05)70952-0
Kurbegovic S, Berg KD, Thomsen FB, Gruschy L, Iversen P, Brasso K, et al. The risk of biochemical recurrence for intermediate-risk prostate cancer after radical prostatectomy. Scand J Urol 2017; 51:450-6. doi.org/10.1080/21681805.2017.1356369
Collado Serra A, Solsona Narbon E. Metodologia diagnostica ante la recidiva bioquímica despues de prostatectomia radical. Arch Esp Urol 2006; 59:1041-52. doi.org/10.4321/S0004-06142006001000011
Ojea Calvo A, Perez Rodriguez A, Domínguez Freire F, Alonso Rodrigo A, Rodriguez Iglesias B, Benavente Delgado J, et al. Recidiva del cáncer de próstata despues de la prostatectomía radical y radioterapia de rescate. Actas Urol Esp 2004; 28:743-8.
doi.org/10.1016/S0210-4806(04)73175-7
Saravia-Rodríguez CE, Diaz-Plasencia JA, Yan-Quiroz EF, Valencia-Marinas H. Factores de riesgo de recurrencia post gastrectomia por carcinoma gastrico. Rev Cuerpo Med HNAAA 2018; 11:69-75. doi.org/10.35434/rcmhnaaa.2018.112.68
Tsilimigras DI, Bagante F, Moris D, Hyer JM, Sahara K, Paredes AZ, et al. Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. Ann Surg Oncol 2020; 27:2321-31.
doi.org/10.1245/s10434-020-08452-3
Sala M, Varela M, Forner A, Bruix J. Diagnostico temprano del cancer de hígado. Gastroenterol Hepatol 2005; 28:292-7. doi.org/10.1157/13074066
Yi X, Luk JM, Lee NP, Peng J, Leng X, Guan X-Y, et al. Association of Mortalin (HSPA9) with Liver Cancer Metastasis and Prediction for Early Tumor Recurrence. Mol Cell Proteomics 2008; 7:315-25. doi.org/10.1074/mcp.M700116-MCP200
Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E. Chemotherapy for recurrent cervical cancer. Cancer Treat Rev 2008; 34:603-13. doi.org/10.1016/j.ctrv.2008.05.006
Paik E, Lim M, Kim M, Kim Y, Song E, Seong S, et al. Prognostic Model for Survival and Recurrence in Patients with Early-Stage Cervical Cancer: A Korean Gynecologic Oncology Group Study (KGOG 1028). Cancer Res Treat 2020; 52:320-33. doi.org/10.4143/crt.2019.124
Lou F, Sima CS, Adusumilli PS, Bains MS, Sarkaria IS, Rusch VW, et al. Esophageal Cancer Recurrence Patterns and Implications for Surveillance. J Thorac Oncol. 2013;8(12):1558-62. doi.org/10.1097/01.JTO.0000437420.38972.fb
Markar S, Gronnier C, Duhamel A, Mabrut J-Y, Bail J-P, Carrere N, et al. The Impact of Severe Anastomotic Leak on Long-term Survival and Cancer Recurrence After Surgical Resection for Esophageal Malignancy. Ann Surg. 2015;262(6):972-80. doi.org/10.1097/SLA.0000000000001011
Sipos JA, Mazzaferri EL. Thyroid Cancer Epidemiology and Prognostic Variables. Clin Oncol. 2010;22(6):395-404. doi.org/10.1016/j.clon.2010.05.004
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018;16(9):1041-1053. doi.org/10.6004/jnccn.2018.0072
Ziaran S, Harsanyi S, Bevizova K, Novakova ZV, Trebaticky B, Bujdak P, et al. Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence. Eur J Histochem. 2020;64(2). doi.org/10.4081/ejh.2020.3098
Gazzaniga P, Gradilone A, Silvestri I, Gandini O, Napolitano M, Vercillo R, et al. High levels of transforming growth factor-alpha (TGF-α) mRNA may predict local relapses in early stage urinary bladder cancer. Eur J Cancer. 1998;34(6):934-6. doi.org/10.1016/S0959-8049(97)10118-6
Selinski S, Bürger H, Blaszkewicz M, Otto T, Volkert F, Moormann O, et al. Occupational risk factors for relapse-free survival in bladder cancer patients. J Toxicol Environ Health A. 2016;79(22-23):1136-43. doi.org/10.1080/15287394.2016.1219606
Sargos P, Baumann BC, Eapen LJ, Bahl A, Murthy V, Roubaud G, et al. Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: Time to reconsider? Transl Androl Urol. 2016;5(5):702-10. doi.org/10.21037/tau.2016.08.18
Nishio K, Kimura K, Amano R, Yamazoe S, Ohrira G, Nakata B, et al. Preoperative predictors for early recurrence of resectable pancreatic cancer. World J Surg Oncol. 2017;15:16. doi.org/10.1186/s12957-016-1078-z
Miki M, Oono T, Fujimori N, Takaoka T, Kawabe K, Miyasaka Y, et al. CLEC3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors. Cancer Med. 2019;8(8):3748-60. https://doi.org/10.1002/cam4.2232
Azizian A, Rühlmann F, Krause T, Bernhardt M, Jo P, König A, et al. CA19-9 for detecting recurrence of pancreatic cancer. Sci Rep. 2020;10:1332. doi.org/10.1038/s41598-020-57930-x
Fischer R, Breidert M, Keck T, Makowiec F, Lohrmann C, Harder J. Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy. Saudi J Gastroenterol. 3 2012;18(2):118-121. doi.org/10.4103/1319-3767.93815
Yu J, Ge X, Luo Y, Shi J, Tan Y, Lai X, et al. Incidence, risk factors and outcome of extramedullary relapse after allogeneic hematopoietic stem cell transplantation in patients with adult acute lymphoblastic leukemia. Ann Hematol. 2020;99(11):2639-48. doi.org/10.1007/s00277-020-04199-9
Ossenkoppele GJ, Janssen JJWM, Loosdrecht AA van de. Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia. Haematologica. 2016;101(1):20-5. doi.org/10.3324/haematol.2015.139105
Hong S, Rybicki L, Corrigan D, Hamilton BK, Sobecks R, Kalaycio M, Gerds AT, Dean RM, Hill BT, Pohlman B, Jagadeesh D, Anwer F, Majhail NS. Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era. Hematol Oncol Stem Cell Ther. 2020 Dec 5:S1658-3876(20)30178-3. doi.org/10.1016/j.hemonc.2020.11.006
Rubio-Anguiano BL, Chavarria-Bravo SM, Nava-Zavala AH, Rubio-Jurado B. Inmunonutrición y cáncer. El residente. 2016; 11: 36-41.
Barajas-Galindo DE, Vidal-Casariego A, Pintor-de la Maza B, Fernández-Martínez P, Ramos-Martínez T, García-Arias S, et al. Postoperative enteral immunonutrition in head and neck cancer patients: Impact on clinical outcomes. Endocrinol Diabetes Nutr. 2020;67(1):13-9. doi.org/10.1016/j.endinu.2019.05.006
Manzanares Campillo M del C, Martín Fernández J, Amo Salas M, Casanova Rituerto D. Estudio prospectivo y randomizado sobre inmunonutrición oral preoperatoria en pacientes intervenidos por cáncer colorrectal: estancia hospitalaria y costos sanitarios. Cir Cir. 2017;85(5):393-400. doi.org/10.1016/j.circir.2016.10.029
Barreiro Domínguez E, Sánchez Santos R, Diz Jueguen S, Piñeiro Teijeiro A, Seoane Antelo J, Carrera Dacosta E, et al. Impacto de la terapia con inmunonutrición oral perioperatoria en pacientes sometidos a cirugía por cáncer colorrectal. Nutr Hosp. 2019;36(5):1150-6. doi.org/10.20960/nh.02548.
Zhang C, Chen B, Jiao A, Li F, Wang B, Sun N, et al. The benefit of immunonutrition in patients undergoing hepatectomy: a systematic review and meta-analysis. Oncotarget. 2017;8(49):86843-52. doi.org/10.18632/oncotarget.20045.
Ochoa JB. Incorporación de la nutrición a las iniciativas de la calidad en cirugía electiva. Rev Nutr Clínica Metab. 2020;3(1):18-20. doi.org/10.35454/rncm.v3n1.025
Ciani F, Cocchia N, Calabrò V, Pollice A, Maruccio L, Carotenuto D, et al. Chapter 45-Uncaria tomentosa: A promising source of therapeutic agents for prevention and treatment of oxidative stress and cancer. In: Preedy VR, Patel VB, editores. Cancer. 2nd edition. San Diego: Academic Press; 2021. p. 505-514.
Kaiser S, Dietrich F, Resende PE de, Verza SG, Moraes RC, Morrone FB, et al. Cat s Claw Oxindole Alkaloid Isomerization Induced by Cell Incubation and Cytotoxic Activity against T24 and RT4 Human Bladder Cancer Cell Lines. Planta Med. 2013; 79:1413-20.
doi.org/10.1055/s-0033-1350742
Ciani F, Tafuri S, Troiano A, Cimmino A, Fioretto BS, Guarino AM, et al. Anti-proliferative and pro-apoptotic effects of Uncaria tomentosa aqueous extract in squamous carcinoma cells. J Ethnopharmacol 2018; 211:285-94. doi.org/10.1016/j.jep.2017.09.031
Aljehani A. Treatment with Extracts of Uncaria Tomentosa Promotes Apoptosis in the Human Breast Cancer Cell Line, MCF7 [Internet]. Canada: Laurentian University of Sudbury; 2015. [Cited 2021 February 26] Available from: https://books.google.com.mx/
books?id=ol5szgEACAAJ
Garcia-Gomez BI, Coronas FI,Restano-Cassulini R, Rodríguez RR, Possani LD. Biochemical and molecular characterization of the venom from the Cuban scorpion Rhopalurus junceus. Toxicon 2011; 58:18-27. doi.org/10.1016/j.toxicon.2011.04.011
Diaz-Garcia A, Morier-Diaz L, Frion-Herrera Y, Rodriguez -Sanchez H, Caballero-Lorenzo Y, Mendoza-Llanes D, et al. In vitro anticancer effect of venom from Cuban scorpion Rhopalurus junceus against a panel of human cancer cell lines. J Venom Res 2013; 4:5-12.
Diaz-Garcia A, Pimentel Gonzalez G, Basaco Bernabeu T, Rodríguez Aurrecochea JC, Rodríguez Sanchez H, Sanchez Monzón I, et al. Pharmacokinetics and Biodistribution of Rhopalurus junceus Scorpion Venom in Tumor-Bearing Mice after Intravenous and Oral
Administration. Iran Biomed J 2019; 23:287-96. doi.org/10.29252/.23.4.287
Diaz-Garcia A, Ruiz-Fuentes JL, Frion-Herrera Y, Yglesi as Rivera A, Garlobo YR, Sanchez HR, et al. Rhopalurus junceus scorpion venom induces antitumor effect in vitro and in vivo against a murine mammary adenocarcinoma model. Iran J Basic Med Sci 2019;
:759-65. doi.org/10.22038/ijbms.2019.33308.7956
Yglesias A, Sánchez H, Diaz Garcia A, Garrido G. Synergistic effect of Rhopalurus junceus scorpion venom combined with conventional cytostatics in cervical cancer cell line HeLa. J Pharm Pharmacogn Res 2019; 7:67-76.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Perla Yazmin Pichardo Jaimes, Hugo Mendieta Zerón, Daniel Viveros Sánchez
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Articles published in the Journal of Dow University of Health Sciences are distributed under the terms of the Creative Commons Attribution Non-Commercial License https://creativecommons.org/ licenses/by-nc/4.0/. This license permits use, distribution and reproduction in any medium; provided the original work is properly cited and initial publication in this journal. 
